Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UMN Pharma Inc and Astellas Pharma Inc Announce Positive Result of Phase III Clinical Trial


Monday, 11 Mar 2013 03:00am EDT 

Astellas Pharma Inc. and UMN Pharma Inc. today announced that the summary results for Phase III clinical trials showed non-inferiority of the recombinant seasonal influenza HA vaccine UMN-0502 (ASP7374) in comparison with the egg-derived vaccine in terms of immunogenicity. No major safety problem was also observed in UMN-0502 (ASP7374) in this study. 

Company Quote

1422.5
8.0 +0.57%
10:30pm EDT